ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile

 

Salix Pharmaceuticals, Ltd. 

1700 Perimeter Park Drive

Morrisville  North Carolina  27560  U.S.A.
Phone: 919-862-1000 Fax: 919-862-1095


SEARCH JOBS


Industry
Pharmaceutical






 Company News
Salix Pharmaceuticals, Ltd. (SLXP) Secures Additional Intellectual Property Relating To Rifaximin 9/18/2014 9:17:33 AM
Salix Pharmaceuticals, Ltd. (SLXP) Faces Shareholder Revolt On Cosmo Pharmaceuticals S.p.A. Deal 9/17/2014 6:33:51 AM
Salix Pharmaceuticals, Ltd. (SLXP) Release: UCERIS® (budesonide) 2mg Rectal Foam For The Induction Of Remission Of Mild-To-Moderate Distal Ulcerative Colitis Granted Tentative Approval By FDA 9/16/2014 8:49:54 AM
Salix Pharmaceuticals, Ltd. (SLXP) Submits Response To XIFAXAN® 550mg Complete Response Letter Regarding Repeat Treatment For Irritable Bowel Syndrome With Diarrhea 9/2/2014 11:53:41 AM
Pharming Group (PHGUF.PK) And Salix Pharmaceuticals, Ltd. (SLXP) Announce Initiation Of Clinical Study Of Ruconest® For Prophylaxis Of Hereditary Angioedema 8/28/2014 10:58:01 AM
Allergan Inc. (AGN) Approaches Salix Pharmaceuticals, Ltd. (SLXP) To Fend Off Valeant Pharmaceuticals International (VRX)'s Hostile Bid 8/20/2014 6:27:57 AM
Salix Pharmaceuticals, Ltd. (SLXP) Announces Early Termination Of HSR Waiting Period For Pending Transaction 8/19/2014 10:15:22 AM
Salix Pharmaceuticals, Ltd. (SLXP) Announces Important Topline Results For Microbiome, Culture & Susceptibility, And Key Secondary Efficacy Results For TARGET 3, Rifaximin IBS-D Repeat Treatment Study 8/12/2014 8:53:48 AM
Salix Pharmaceuticals, Ltd. (SLXP) Release: FDA Assigns September 29, 2014 Prescription Drug User Fee Act Goal Date For RELISTORĀ® Subcutaneous Injection Snda For The Treatment Of Opioid-Induced Constipation In Patients With Chronic Non-Cancer Pain 8/11/2014 8:24:49 AM
Salix Pharmaceuticals, Ltd. (SLXP) Announces 2Q2014 Financial Results Conference Call And Webcast 7/24/2014 12:56:43 PM
12345678910...